BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 6298169)

  • 1. Cefoxitin, N-formimidoyl thienamycin, clavulanic acid, and penicillanic acid sulfone as suicide inhibitors for different types of beta-lactamases produced by gram-negative bacteria.
    Sawai T; Tsukamoto K
    J Antibiot (Tokyo); 1982 Nov; 35(11):1594-602. PubMed ID: 6298169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors.
    Moosdeen F; Keeble J; Williams JD
    Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulbactam: biochemical factors involved in its synergy with ampicillin.
    Labia R; Morand A; Lelievre V; Mattioni D; Kazmierczak A
    Rev Infect Dis; 1986; 8 Suppl 5():S496-502. PubMed ID: 3025996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of beta-lactamase inhibitors with various beta-lactamases.
    Cullmann W
    Chemotherapy; 1990; 36(3):200-8. PubMed ID: 2159863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of beta-lactamase inhibition: differences between sulbactam and other inhibitors.
    Sawai T; Yamaguchi A
    Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):121S-129S. PubMed ID: 2591172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of the effect of beta-lactamase inhibitors on the beta-lactamase in growing cultures of gram-negative bacteria with their effect on the isolated beta-lactamase.
    Easton CJ; Knowles JR
    Antimicrob Agents Chemother; 1984 Sep; 26(3):358-63. PubMed ID: 6095753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penicillanic acid sulfone: nature of irreversible inactivation of RTEM beta-lactamase from Escherichia coli.
    Brenner DG; Knowles JR
    Biochemistry; 1984 Nov; 23(24):5833-9. PubMed ID: 6098299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic studies on inactivation of Citrobacter freundii cephalosporinase by sulbactam.
    Yamaguchi A; Hirata T; Sawai T
    Antimicrob Agents Chemother; 1983 Jul; 24(1):23-30. PubMed ID: 6312873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies.
    Cullmann W
    Zentralbl Bakteriol; 1991 Oct; 275(4):500-3. PubMed ID: 1661596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino acid sequence, active-site residue, and effect of suicide inhibitors on cephalosporinase of Citrobacter freundii GN346.
    Sawai T; Yamaguchi A; Tsukamoto K
    Rev Infect Dis; 1988; 10(4):721-5. PubMed ID: 3263684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of azlocillin in combination with clavulanic acid, sulbactam, and N-formimidoyl thienamycin against beta-lactamase-producing, carbenicillin-resistant Pseudomonas aeruginosa.
    Calderwood SB; Gardella A; Philippon AM; Jacoby GA; Moellering RC
    Antimicrob Agents Chemother; 1982 Aug; 22(2):266-71. PubMed ID: 6100423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
    Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel carbapenem derivative SF2103A: studies on the mode of beta-lactamase inactivation.
    Yamaguchi A; Hirata T; Sawai T
    Antimicrob Agents Chemother; 1984 Mar; 25(3):348-53. PubMed ID: 6372682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of aztreonam as a substrate, inhibitor and inducer for beta-lactamases.
    Sakurai Y; Yoshida Y; Saitoh K; Nemoto M; Yamaguchi A; Sawai T
    J Antibiot (Tokyo); 1990 Apr; 43(4):403-10. PubMed ID: 2112533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-(Methoxymethylene)penicillanic acid: inactivator of RTEM beta-lactamase from Escherichia coli.
    Brenner DG; Knowles JR
    Biochemistry; 1984 Nov; 23(24):5839-46. PubMed ID: 6098300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sulbactam and clavulanic acid: studies of enzyme kinetics and synergism with ampicillin and mezlocillin].
    Cullmann W; Binder S; Stieglitz M
    Immun Infekt; 1987 May; 15(3):103-9. PubMed ID: 3038733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam.
    Chin NX; McElrath MJ; Neu HC
    Chemotherapy; 1988; 34(4):318-25. PubMed ID: 2850139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
    Grace ME; Fu KP; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.